menu

ReachMD

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Advances in the Treatment of Glioblastoma Multiforme: Is There a Role for Immune Checkpoint Inhibitors?

Despite significant progress in the treatment for glioblastoma multiforme, or GBM, patient outcomes have failed to see a drastic improvement. Recen...

Available credits: 0.50

Time to complete: 30 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Despite significant progress in the treatment for glioblastoma multiforme, or GBM, patient outcomes have failed to see a drastic improvement. Recently, immune checkpoint inhibitors have shown promise in treating patients with GBM in cases where conventional treatment options have failed. The rapid progression of GBM necessitates timely and well-informed decisions made on the part of the clinician. This activity will provide the participant with up-to-date evidence regarding the immune system of patients with GBM as well as ongoing and recent clinical data regarding immune checkpoint inhibitors as treatment options.

    Selected References

    • Andtbacka RH et al. J Clin Oncol. 2015;33:2780-2788.
    • Robert C et al. Lancet. 2014;384:1109-1117.
    • Fecci PE et al. Clin Cancer Res. 2007;13:2158-2167.
    • Garber ST et al. Neuro-Oncology. 2016;18:1357-1366.
    • Hodi FS et al. N Engl J Med. 2010;363:711-723.
    • Jiang et al. Nat Med. 2016;22:851-860.
    • Kantoff. N Engl J Med. 2010;363:411.
    • Kim et al. Clin Cancer Res. 2017;23:124-136.
    • Pardoll DM. Nat Rev Cancer. 2012;12:252-264.
    • Weber J. Semin Oncol. 2010;37:430-439.
    • Zaretsky JM et al. N Engl J Med. 2016;375:819-829.
    • Zeng J et al. Int J Radiat Oncol Biol Phys. 2013;86:343-349.
  • Learning Objectives

    • Describe the latest evidence providing rationale for targeting the immune system in the treatment of GBM.
    • Evaluate results of ongoing clinical trials examining immunotherapy agents as part of GBM treatment paradigms.
    • Recognize strategies to manage the unique adverse events related to the use of immunotherapy in GBM. 

    The Johns Hopkins University School of Medicine and The Institute for Johns Hopkins Nursing take responsibility for the content, quality, and scientific integrity of this CME/CNE activity.

  • Target Audience

    This activity is primarily intended for neuro-oncologists, neurosurgeons, neuropathologists, radiology and medical oncologists. NPs/PAs, oncology nurses and clinical oncology pharmacists will also find this material beneficial.

  • Faculty

    Full Disclosure Policy Affecting CME Activities
    As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) requires attested and signed global disclosure of the existence of all financial interests or relationships with commercial interest from any individual in a position to control the content of a CME activity sponsored by OCME.

    Policy on Faculty and Provider Disclosure
    It is the policy of the Johns Hopkins University School of Medicine and The Institute for Johns Hopkins Nursing that the speaker and provider globally disclose conflicts of interest. The Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the instructional materials.

    The following relationships have been reported for this activity:

    Michael Lim, MD (Chair/Planner)
    Associate Professor, Neurosurgery, Oncology, Radiation Oncology
    Institute of Nanobiotechnology
    Director, Brain Tumor Immunotherapy Program
    Director, Metastatic Brain Tumor Center
    Johns Hopkins University School of Medicine

    Planner Disclosures
    Dr. Lim reports receiving research grants/research support from and serving as a consultant for Agenus Inc and Bristol-Myers Squibb Company; receiving grants/research support from Accuray Incorporated, Arbor Pharmaceuticals, Celldex Therapeutics, and ImmunoCellular Therapeutics Ltd; serving as a consultant for Boston Biomedical and Oncor Inc; and, receiving honoraria from Regeneron Pharmaceuticals Inc and Stryker Corporation.

    Accreditation Statements 
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

    The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

    Credit Designation Statements 
    The Johns Hopkins University School of Medicine designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    This .5 contact hour educational activity is provided by the Institute for Johns Hopkins Nursing. Claim only those contact hours actually spent in the activity. Statements will be awarded for this educational activity until March 17, 2018.

    Non-Endorsement of Products
    The Institute for Johns Hopkins Nursing and the American Nurses Credentialing Center do not endorse the use of any commercial products discussed or displayed in conjunction with this educational activity.

  • Provider(s)/Educational Partner(s)

              

    This activity was developed in collaboration with ASiM.

  • Commercial Support

    Supported by an educational grant from Bristol-Myers Squibb Company.

  • Disclaimer

    The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.

    Confidentiality Disclaimer for CME Activity Participant
    I certify that I am participating in this Johns Hopkins University School of Medicine activity for CME-accredited training and/or educational purposes.

    I understand that while I am participating in this capacity, I may be exposed to "protected health information," as that term is defined and used in Johns Hopkins policies and in the federal HIPAA privacy regulations (the "Privacy Regulations"). Protected health information is information about a person’s health or treatment that identifies the person. I also understand that while I am participating in this capacity I will be treated as a temporary member of Johns Hopkins for purposes of the Privacy Regulations only.

    I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.

    “The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as sponsor of this activity, has relayed information with the CME attendees/participants and certify that the visitor is here for training, education and/or observation purposes only.”

    Johns Hopkins University School of Medicine
    Office of Continuing Medical Education
    720 Rutland Avenue/ Turner 20
    Baltimore, Maryland 21205-2195
    Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (4/1/09)

  • The Institute for Johns Hopkins Nursing Mission Statement

    The mission of The Institute for Johns Hopkins Nursing is to share the innovations of Johns Hopkins Nursing in practice, education, and research—locally, nationally, and globally.

    Our goal in continuing nursing education is to bring you activities that reflect the expertise and creativity of Johns Hopkins Nursing. Our service values are quality, integrity, flexibility, and personal attentiveness. We appreciate your thoughts and welcome your concerns—please feel free to e-mail us: IJHN@son.jhmi.edu.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience."

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.